Tryptamine Therapeutics Limited - Neraca (Quarterly)

Tryptamine Therapeutics Limited
AU ˙ ASX
A$ 0.03 ↑0.00 (6.25%)
2025-09-05
BAHAGING PRESYO
Talaan ng Balanse (Quarterly)

Neraca Tryptamine Therapeutics Limited menunjukkan saldo akun perusahaan pada titik waktu tertentu. Data Neraca meliputi Aset, Aset Lancar, Aset Tetap, Properti, Pabrik dan Peralatan (PPE), Persediaan, Aset Tak Berwujud, Kewajiban, Kewajiban Lancar, Utang, Kewajiban Sewa Modal, Saham Biasa, Laba Ditahan, Saham Perbendaharaan, dan Ekuitas Pemegang Saham.

Semua angka adalah kelipatan 1,000,000.00 kecuali unit per saham.

2021
05-31
2021
08-31
2021
11-30
2022
02-28
2022
05-31
2022
08-31
2022
11-30
2023
02-28
2023
05-31
2023
08-31
2023
11-30
2024
02-29
2024
06-30
2025
06-30
Cash 6 4 2 1 3 2 1 0 1 0 2 0 5 3
Change (%) -35.15 -42.67 -68.02 327.15 -36.38 -53.93 -94.74 2,852.85 -65.79 366.13 -76.90 1,017.37 -43.19
Assets Current 6 4 2 2 3 2 1 0 1 1 2 1 7 6
Change (%) -32.73 -42.89 2.85 40.64 -35.51 -49.51 -69.23 329.82 -62.15 296.70 -72.33 1,073.60 -10.34
Assets 6 4 2 2 4 2 1 1 2 1 2 1 7 7
Change (%) -32.51 -42.13 4.84 41.23 -33.56 -46.06 -60.28 224.10 -54.10 215.65 -66.10 834.41 -10.60
Liabilities 0 0 1 2 1 1 2 2 4 5 7 7 2 1
Change (%) 56.23 300.60 112.53 -65.16 117.39 31.07 26.85 82.81 38.65 43.84 2.64 -75.36 -61.85
Equity 6 4 2 1 3 1 -0 -1 -2 -4 -5 -7 6 6
Change (%) -34.27 -58.33 -44.07 224.90 -61.51 -126.70 386.88 35.17 113.62 14.00 35.69 -184.66 6.12
Liabilities And Stock Equity 6 4 2 2 4 2 1 1 2 1 2 1 7 7
Change (%) -32.51 -42.13 4.84 41.23 -33.56 -46.06 -60.28 224.10 -54.10 215.65 -66.10 834.41 -10.60

Source: Capital IQ

Other Listings
US:TYPTF
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista